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Abstract 
 
Imprinting disorders (IDs) are a group of congenital diseases affecting growth, development 
and metabolism. They are caused by changes in the allele-specific regulation (“epigenetic 
mutation”) or in the genomic sequence (“genetic mutation”) of imprinted genes. Currently 
molecular tests in ID patients are generally restricted to single loci classically associated with 
the disease, but this approach limits diagnostic yield, because of the molecular and clinical 
heterogeneity between IDs. From the technical point of view, these limitations are aggravated 
by the lack of standardization in testing methodology, in the DNA sequences tested, and in 
clinical inclusion criteria prompting testing.  
However, an increasing number of new studies show that these problems can be addressed by 
the use of new tests targeting multiple loci and/or a total exome and genome analysis.  
The rapid development of efficient and high-throughput molecular techniques and their 
applications in research and diagnostics in the last decade have led to an impressive increase 
of knowledge on IDs and their basic pathomechanisms. In combination with the improvement 
of data recording and documentation, the diagnostic strategies are increasingly based on 
standardized protocols, and thereby provide the backbone for directed counselling, more 
personalized management, and new therapeutic approaches.  
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1. Introduction 
 
Imprinting disorders (IDs) are a group of congenital diseases affecting growth, development 
and metabolism characterised by similar molecular alterations (Table 1).  
They are caused by changes in the allele-specific regulation (“epigenetic mutation”) or in the 
genomic sequence (“genetic mutation”) of imprinted genes and regions, respectively (Figure 
1). In contrast to the majority of biallelically expressed genes, imprinted genes are expressed 
monoallelically in a parent-of-origin specific manner - i.e. either from the maternal or the 
paternal allele (for review: [1]). At the molecular level, the expression of genes within 
imprinted regions is influenced by specific patterns of DNA methylation, changes in 
chromatin structure, and post-translational histone modifications, collectively designated as 
epigenetic regulation (for review: [2, 3]). So far, more than 90 human genes have been 
confirmed to be imprinted, but there are probably more based on bioinformatics predictions 
(for review: http://www.geneimprint.com/site/home, [www.geneimprint.com/site/genes-by-
species] last check: 19.04.2015). The normal imprinting marks are inherited from the parental 
gametes and are then maintained in the majority of somatic cells and tissues of an individual. 
Their programming is subject to an imprinting cycle during life which leads to a 
reprogramming at each generation (for review: [4, 5]). Methylation of the mammalian 
genome is comprehensively remodelled in early development. However, imprinting marks are 
exempted from developmental reprogramming; instead, they are erased in the germ-line and 
re-established according to the sex of the contributing parent for the next generation. Many 
genes regulated by genomic imprinting are found in clusters, i.e. imprinted loci often 
comprise multiple genes under coordinated control. A prominent example is the chromosomal 
region 11p15.5 which harbors genes encoding several growth promoting and inhibiting 
factors. It spans around 1 Megabase (Mb) and maintains two separate imprinting control 
regions (ICRs): the telomeric imprinting control region 1 (ICR1; H19 differentially 
methylated region - DMR) is methylated on the paternal allele, whereas the centromeric ICR2 
(KvDMR1; KCNQ1OT1 DMR) is maternally methylated. In addition to its central 
physiological role in human growth and development it has been postulated that the 11p15.5 
region is a central element of a network of imprinted genes [6, 7].  
 
2. Imprinting Disorders (IDs): (epi)genetic aetiology and phenotypes 
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ID patients carry molecular disturbances which result in an unbalanced expression of 
imprinted genes. So far, four different types of alterations have been reported (Figure 1), (i) 
uniparental disomy (UPD), (ii) deletions or duplications of the imprinted region, (iii) aberrant 
methylation marks (called epimutations), and (iv) point mutations in (imprinted) genes (see 
below). It is assumed that these (epi)mutations cause unbalanced expression of imprinted 
genes and thereby the clinical features of IDs, but functional proof of this is lacking in the 
majority of IDs. 
In several IDs, two  additional molecular features may be present: (a) mosaic distribution of 
epimutations and UPD, i.e. not all cells carry the disturbance causative of disease; and (b) the 
occurrence of multilocus imprinting defects (MLID) in a proportion of patients with 
epimutations (table 1) 
 
For the majority of the known IDs and their molecular defects, the pathophysiological 
mechanisms resulting in the specific phenotypes are unknown. So far only three genes have 
been shown to be directly associated with clinical phenotypes (Table 1): CDKN1C in 
Beckwith-Wiedemann syndrome and Silver-Russell-Syndrome (BWS, SRS), UBE3A in 
Angelman syndrome (AS) and MKRN3 in central precocious puberty [8]. These genes are 
themselves imprinted; as a result, the inheritance of mutations in UBE3A and CDKN1C is 
autosomal dominant but its penetrance depends on the sex of the contributing parent.  
The impact of genomic mutations in imprinted genes on the clinical outcome has furthermore 
been shown for mental retardation: maternally inherited KCNK9 mutations  have been 
identified to cause the Birk-Barel mental retardation syndrome [9]. 
 
 
An indirect cause of IDs is the mutation of genes encoding factors involved in the 
establishment and maintenance of imprinting. One such factor is the ZFP57 gene mutations in 
which cause MLID and is inherited in an autosomal recessive manner. Interestingly, ZFP57 
mutations have never been except in association with clinical presentation of transient 
neonatal diabetes mellitus (TNDM), An additional group of factors associated with aberrant 
methylation are the NLRP genes, but mutations in these genes act as maternal effect 
mutations, that means the maternal genotype causes aberrant methylation in the offspring [10, 
11].  
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So far, ten IDs have been reported (Table 1) and the clinical and molecular definition of 
further disorders is a matter of active discussion. The majority of IDs share major clinical 
characteristics, i.e.: 
- pre- and/or postnatal growth retardation or pre- and postnatal overgrowth; 
- hypo- or hyperglycemia; 
- abnormal feeding behavior in early childhood and later 
- behavioral difficulties (in childhood) 
- precocious puberty. 
 
Nearly all patients with an ID are diagnosed in (early) childhood. However, clinical diagnosis 
is often hampered by the breadth of the phenotypic features which are sometimes subtle, 
overlapping and transient; this latter point in particular can obscure diagnosis in puberty and 
adulthood. As a result some IDs and a proportion of patients are probably either mis- or 
undiagnosed.  
 
3. Currently applied single-locus tests and their limitations 
 
Up to now, molecular tests in ID patients are generally restricted to single disease-specific 
loci. Thus, the detection rates for epimutations or mutations at these loci are more or less well 
established. However, technical, biological and clinical factors influence the diagnostic yield 
in IDs, and thereby limit the diagnostic detection rates. 
 
3.1 Limitation 1: lack of standardization of the applied tests 
A broad range of molecular techniques with different sensitivities is applied in diagnostic 
testing of IDs (Table 2), and they often target different differentially methylated CpG 
dinucleotides and even different differentially methylated regions (Figure 2). Due to this lack 
of standardization, it is difficult to compare the molecular results between different studies or 
laboratories offering molecular diagnosis for the same disorder. However, as data for the 
GNAS locus reveals, the heterogeneity of molecular tests affects the detection of mosaic 
(epi)mutations rather than the correctness of the molecular diagnosis [12]. 
 
3.2 Limitation 2: Heterogeneity of the aetiology in IDs 
The heterogeneity of molecular aetiology in IDs has become apparent with the increased use 
of methods capable of parallel detection of mutations and epimutations at different loci 
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(multilocus methylation tests, array typing, Next Generation Sequencing/NGS; Table 3). 
Recently, we reported on our results from a cohort of 711 patients referred with the clinical 
diagnosis of one of the two chromosome 11p15-associated IDs, SRS (n=571) or BWS 
(n=140). Molecular testing was not restricted to the 11p15 imprinted loci, but also 
encompassed differentially methylated regions (DMRs) on chromosomes 6, 7, 14 and 15 [13]. 
In the course of this study, several patients were identified with unexpected alterations, 
affecting other loci than those on chromosome 11. These non-11p15 disturbances eluded 
routine diagnostic screening restricted to 11p15, but have significant impacts because they (a) 
help to define novel connections between imprinting disturbances and clinical features, and 
(b) increase the diagnostic yield [14]. 
As already mentioned, some IDs frequently show somatic mosaicism.  This is particularly 
recognized for epimutations in SRS and BWS. The level of mosaicism shows a broad range, 
and can differ remarkably between different tissues [15, 16]. Therefore, if the tissue source of 
the diagnostic DNA sample has a level of mosaicism below the sensitivity of the diagnostic 
test, the result will be negative and the patient will escape diagnosis.  The limited sensitivity 
of current single-locus tests therefore restricts diagnostic yield. Another limitation of the 
single-locus tests is that many of them do not differentiate different classes of mutations and 
epimutations associated with IDs (e.g. UPD, epimutation) (Figure 1, Table 2). 
 
3.3 Limitation 3: ambiguous findings in I s 
Ambiguous clinical findings in IDs further challenge the value of current single-locus tests.  
The same clinical diagnosis may be associated with molecular alterations at different DMRs 
(e.g. ICR1 and ICR2 in 11p15 in BWS) and even at chromosomal loci (e.g. SRS: 
chromosomes 7 and 11;  Table 1). This locus heterogeneity is further complicated by the 
possible occurrence of up to four different classes of mutations or epimutations. A prominent 
example is the recent discovery that CDKN1C gain-of-function mutations are associated with 
a clinical presentation very similar to SRS; this new aetiology complements the known causes 
of SRS clinical features, which include ICR1 hypomethylation, maternal UPD11 and 11p15 
duplications [17, 18, 19, 20], not to mention maternal UPD7, and chromosomal aberrations.   
 
The broadening of molecular testing shows that there is a considerable overlap between the 
different IDs, and the application of single-locus test can prevent the diagnosis of basic 
molecular defects and thus leave a patient without diagnosis. One example is the changing 
phenotype in the previously identified Temple syndrome (TS14), a congenital disorder linked 
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to imprinted loci on 14q32. Until recently, TS14 was regarded as a differential molecular 
diagnosis of Prader-Willi syndrome (PWS), but the broadening of genetic testing shows that 
the TS14 phenotype is heterogeneous, overlaps in early childhood with that of SRS, and is not 
mandatorily associated with (mild) psychomotoric retardation [21]. The impressive result of 
the application of multilocus tests in ID diagnostics is therefore obvious as a growing number 
of patients with Temple syndrome (TS14) can be identified among patients referred as SRS 
[22].  This illustrates the need for a comprehensive diagnostic algorithm in the testing of SRS. 
Furthermore, a considerable number of ID patients exhibit the above mentioned aberrant 
methylation at different imprinted loci (multilocus imprinting disturbances; MLID) [23] or 
carry at least two different molecular disturbances [24, 25] which escape single-locus testing. 
These patients often show a broad clinical spectrum and the phenotype may be ambiguous or 
even atypical for any known ID. In summary, as Table 1 shows, a similar molecular 
heterogeneity is known for the majority of IDs, and this heterogeneity is not captured by 
many of the available tests (Table 2). 
 
5. Translational use of new techniques in IDs 
 
An increasing number of new studies show that the aforementioned problems in diagnosis and 
investigation of IDs can be addressed by the use of new tests targeting multiple loci and/or a 
total exome and genome analysis.  
 
One major prerequisite for the comprehensive diagnostic analysis of ID loci is the 
identification and definition of a standardized set of imprinted loci, DMRs and CpG islands. 
With the extensive characterization of imprinted methylation in molecularly normal and 
aberrant human tissues by a combination of whole-genome bisulfite sequencing and high-
density methylation microarrays, Court and colleagues [26] recently laid the foundation for 
the development of harmonized tests. Another important step is the use of a controlled and 
standardized vocabulary for describing clinical entities, as is now provided by HPO (human 
phenotype ontology, http://www.human-phenotype-ontology.org/). To make the huge number 
of mutations and epimutations from different diagnostic and research institutions available to 
the public, the common use of LOVD (Leiden open variation database) as the common 
variation database is suggested (http://www.lovd.nl/3.0/home) (Figure 3).  
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The need for comprehensive testing to identify multiple and complex molecular alterations in 
ID patients and their clinical significance has been illustrated by numerous case reports and 
studies. For instance, in a patient with clinical features characteristic for Beckwith-
Wiedemann syndrome (BWS; macrosomia, macroglossia, ear pits) and additional features 
(mental retardation, cardiac malformation, facial dysmorphisms), a paternal 11p15 duplication 
was identified by methylation-specific (MS) multiplex ligation-dependent probe amplification 
(MS-MLPA) [27]. Further characterization by SNP (single nucleotide polymorphism) array 
analysis and fluorescence in-situ hybridization (FISH) confirmed a 2.6 Mb duplication in 11p, 
but additionally identified a 4.9 Mb deletion in 18q22.3. Segregation analysis confirmed that 
the father and further family members were carriers of a balanced 11p/18q translocation. With 
the identification of the two different imbalances, the unusual clinical pattern in the patient 
could be explained, and the family could be precisely counseled. This case impressively 
illustrates the need and the power of the combined application of different tests. The exclusive 
use of the initial MS-MLPA restricted to 11p15 would have explained the BWS features, but 
not the other features, and particularly a lower recurrence risk would have been delineated for 
the family. 
Another example for the impact of multilocus testing in IDs is the growing number of reports 
on BWS patients with a mosaic genome-wide paternal diploidy meaning that a significant 
ratio of cells carry chromosomes exclusively derived from the father.  It turns out that a 
considerable number of BWS patients diagnosed to have an UPD(11p15)pat carry this 
unusual aberration [13], Considering that UPD(11p15)pat accounts for nearly 20% of BWS 
patients, and that carriers of a mosaic genome-wide paternal diploidy exhibit particularly 
unusual tumor histories which are not covered by the already existing surveillance programs 
for classical BWS [28], every case of UPD(11)pat warrants testing for genome-wide 
uniparental diploidy [29]. 
 
As already mentioned, somatic mosaicism is a common finding in IDs. In particular in the 
11p15-associated disorders (BWS and SRS), nearly all patients with epimutations and UPD 
show mosaicism (for review: [13]). As a consequence of mosaicism, the molecular alterations 
currently often escape diagnostic detection in case of a low level mosaicism [30], an unequal 
distribution in different tissues [15], or an insufficient sensitivity of assays [31, 32]. New 
diagnostic approaches therefore may analyze different tissues from the same patient as well as 
apply multilocus and/or deep-sequencing tests.  
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The suitability of genome-wide SNP arrays for mosaicism detection has recently been 
demonstrated by Keren et al. [29]. Their data exhibited that SNP arrays are useful tools to 
estimate the sizes and mosaicism rates of UPD(11p15)pat  as the basis for a more precise 
genotype phenotype correlation. The power to detect low-level mosaicism by array analysis 
was additionally confirmed by Prickett et al. [33] in a cohort of SRS patients: by 
hybridization of patients DNA onto DNA methylation microarrays the group provided proof 
of principle that this technique has a higher sensitivity than classical conventional single-
locus tests. Additionally, the use of methylation arrays contributes to the idenfication of novel 
candidate imprinted genes, and the epigenomic profiling expands the understanding of normal 
methylome and its disruption [34].  
For the same purposes, deep-sequencing NGS assays have been developed, and it has been 
shown that this technique is able to detect even low-level mosaicism [31, 32]. As it is 
generally observed for genetic testing, NGS will also improve the diagnostic workup in 
imprinting disorders, even in so far unexpected fields like non-invasive prenatal testing [35]. 
 
6. The new techniques contribute to the understanding of the pathoetiology of IDs 
 
The aforementioned examples show that the application of multilocus and deep sequencing 
molecular tests are needed in ID diagnostics. 
However, diagnostics and research should be regarded not as separate, but synergistic: the 
identification of new molecular alterations in ID patients enlighten the pathomechanisms in 
these heterogeneous disorders, while the data obtained from research strategies are 
translationally used for the improvement of diagnostic workups (Figure 3). This close relation 
between research and diagnostics will be illustrated with the following examples. 
 
6.1 ZFP57 mutations causing autosomal-recessively inherited IDs 
In seven consanguineous families affected by the ID transient neonatal diabetes the genome-
wide SNP array analysis delineated a single shared ~15Mb region of homozygosity on 
chromosome 6. Prioritization of candidate genes within this region prompted Sanger 
sequencing of the zinc-finger transcription factor ZFP57, which was shown to be mutated in 
all the consanguineous pedigrees [36].  ZFP57 was independently shown in mouse to be 
essential for maintenance of imprinting marks in early development [37]. Moreover, in 
ethnicities with a high social rate of consanguineous union, ZFP57 mutations may be the 
major cause of transient neonatal diabetes [38].   
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6.2 Families with NLRP mutations 
Mutations of NLRP family genes NLRP7 and NLRP2 are associated with reproductive loss, 
where the females with these mutations gave birth to few or no liveborn children. Instead 
hydatidiform molar pregnancies with loss of maternal imprinting marks occurred.  Caliebe et 
al. [39] reported exhaustive genetic and epigenetic analysis of a pedigree with two children 
with MLID.  Exome sequencing identified a heterozygous missense variant in NLRP7 in the 
mother of the children.  Interestingly, she had inherited this variant from her mother and both 
genome-wide and targeted DNA methylation analysis showed that she, like her offspring, had 
MLID. 
 
6.3 Identification of CDKN1C mutations as monogenetic causes of ID phenotypes 
As with other genetic fields, deep sequencing NGS has significantly contributed to the 
understanding of IDs. Loss-of-function CDKN1C mutations are well known to be associated 
with BWS, but the first gain-of-function variants have been identified in patients with IMAGe 
syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia 
congenita, genitourinary abnormalities)[40] and later in SRS [20]. This finding was 
remarkable in at least three different ways: (a) functionally, the opposite phenotypic outcomes 
of BWS vs. IMAGe/SRS could be explained by the opposite functional properties of the 
mutations (for review: [41]); (b) gain-of-function mutations cause growth restriction only in 
maternal inheritance, because CDKN1C is expressed only from the maternal allele, and 
therefore IMAGe syndrome can be regarded as an ID; (c) CDKN1C also illustrated the 
limitations of NGS. Due to its high GC content, the NGS coverage for CDKN1C was much 
lower than for other genomic regions, and was only identified after its sequence was 
reanalyzed with the Sanger method [40], and furthermore, the bioinformatics analysis had to 
be adapted to a pedigree model with an influence of the parent-of-origin of putative 
mutations.  
 
6.4 NGS-based quantification of aberrant methylation contributes to the understanding 
of regulation of imprinting centers 
As it could be recently shown by Beygo et al. [32], NGS-based approaches can also help to 
understand the functional interaction between different DMRs on the same imprinting center. 
One example is the chromosomal region 14q32, harboring the IG-DMR and the MEG3-
DMR,.Genetic aberrations affecting these DMRs are associated with TS14 or Kagami-Ogata 
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Syndrome  (KOS14, formerly known as paternal UPD14 syndrome). Based on the precise 
characterization of patients with small deletions in 14q32, affecting either the MEG3/DLK1 
IG-DMR or the MEG3-DMR itself by quantitative next generation sequencing of bisulfite 
treated DNA samples,  it could be shown that the two different DMRs have individual 
functional properties and a hierarchical order in that way that the IG-DMR is the dominant 
germline DMR and regulates the MEG3-DMR [32, 42]. 
 
7. Consequences of comprehensive analyses in IDs for their therapy 
 
As already shown, the application of the new comprehensive and efficient laboratory tests in 
the diagnostic of IDs is resulting in an increase of patients with a molecular proven disorder. 
In particular the use of multilocus tests helps to identify patients with unexpected molecular 
alterations (e.g. with TS14-specific alterations in a cohort of SRS patients), to enlighten the 
molecular basis in case of unusual phenotypes [24] and to detect MLID carriers. In the latter 
group, it is currently discussed whether patients with MLID and a specific ID diagnosis have 
phenotypes different from those with “isolated” epimutations or mutations restricted to the 
disease-specific locus. Here further data are needed, however due to the first reports of 
monogenetic causes in MLID, genetic counselling might be different. 
In general, the more precise determination of the molecular basis of a clinical picture is the 
basis for a more personalized treatment and management. One example is the recently 
reported evidence for different responses of SRS patients with different molecular 
disturbances on growth hormone treatment [43]. These findings can be regarded as a first step 
towards a more individual GH substitution. Another ideal example is the identification of 
genome-wide uniparental diploidy patients in the group of BWS patients: these patients' 
tumor history and risks are different from those of UPD11pat alone, and therefore require 
another tumor surveillance program [28]. 
 
Potentially the new therapeutic options for IDs which can be delineated from the rapid 
development of new methods are more promising. With the exception of those patients with 
chromosomal aberrations or gene mutations, carriers of epimutations can have a normal 
genome. This means these patients carry intact, but silenced alleles. Thus, these defects 
should in principle be curable by reversing the aberrant imprinting mark. With the growing 
knowledge on the molecular basis of aberrant imprinting from experimental models and the 
development of powerful strategies towards cell replacement therapies, e.g. induced 
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pluripotent stem cells (iPS) and the gene editing CRISPR/Cas system, promising milestones 
towards a causative therapy have been undertaken [44, 45, 46]. 
 
Conclusions 
 
The rapid development of efficient and high-throughput molecular techniques and their 
application in research and diagnostics in the last decade have led to an impressive increase of 
knowledge on IDs and their basic pathomechanisms. In combination with the improvement of 
data recording and documentation, the diagnostic strategies are increasingly based on 
standardized protocols, and thereby provide the backbone for a directed counselling as well as 
of a more personalized conventional and new therapeutic approach.  
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Tables and Figures 
 
 
Table 1:   The known congenital disorders associated with disturbances at imprinted loci, their frequencies, and the associated molecular and 
clinical findings. (NR not yet reported, IUGR intrauterine growth retardation, PNGR postnatal growth retardation, PTH parathormone; hypom. 
hypomethylation; hyperm. hypermethylation)(*absolute numbers for the frequencies of the molecular subtypes are taken from representative studies 
or reviews; ** in case of AS and PWS these frequencies are well established from huge cohorts and therefore not documented by specific 
references) 
 
Table 2:  Methylation-specific (MS) assays applied in diagnostics and research of imprinted loci. 
 
Figure 1: Four different molecular mechanisms affecting imprinted regions can be detected in IDs, they all result in a disturbed expression of 
imprinted genes. 
 
Figure 2: Physical localization of the target CpGs in 11p15.5 of the different molecular tests applied by the contributing groups. The CpGs 
detected by the MS-MLPA assay are marked by asterisks, the CpG stretches covered by the other tests are shown as bars. (*On the Y axis, the 
methylation is indicated, for imprinted loci an averaged methylation of 50% can be observed.)  
Figure 3: Application of standardized and harmonized methods for recording, documentation and diagnostic as the basis for research and 
personalized medicine. These exchanges and interactions are main topics of the European network of congenital imprinting disorders 
(www.imprinting-disorders.eu). 
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Table 1 
Disorder Chromosomal 
region 
Molecular 
Disturbance 
Frequencies 
(n=) 
Multilocus 
Defects 
Clinical features 
Transient Neonatal 
Diabetes mellitus  
(TNDM) 
6q24 UPD(6)pat 
dup(6q) 
PLAGL1 hypom. 
  ZFP57 mutations 
41% 
29% 
30% 
   50% 
(n=163) [34] 
50% IUGR, transient diabetes, hyperglycemia 
without ketoacidosis, macroglossia, 
omphalocele 
Silver-Russell 
syndrome (SRS) 
7 UPD(7)mat 7-10% 
(n=109)[13] 
1 case IUGR/PNGR, rel. macrocephaly, 
hemihypotrophy, triangular face, feeding 
difficulties 11p15.5 
 
UPD(11)mat 
dup(11p15)mat 
ICR1 hyp. 
CDKN1C mutations 
IGF2 mutations 
n=1 
1-2% 
>38%  
n=1 
n=1 
(n=109)[13] 
- 
- 
~10% 
- 
- 
Beckwith-Wiedemann 
syndrome (BWS) 
 UPD(11)pat 
   Genomewide  
    paternal UPD 
dup(11p15)pat 
ICR1 hyperm. 
ICR2 hypom. 
CDKN1C mutations 
20% 
~ 10%? 
~  90% 
1-2% 
4% 
50% 
5% 
[n=40)[13] 
- 
 
 
- 
- 
25% 
- 
pre- and postnatal overgrowth, organomegaly, 
macroglossia, omphalocele, neonatal 
hypoglycemia, hemihypertrophy, increased 
tumour risk 
Temple syndrome 
(UPD(14)mat) 
14q32 UPD(14)mat 
del(14q32)pat 
MEG3 hypom. 
78.4% 
9.8% 
11.7% 
(n=51)[21] 
- 
- 
NR 
IUGR,PNGR, Hypotonia, feeding difficulties 
in infancy, truncal obesity, scoliosis, 
precocious puberty 
Kagami-Ogata 
syndrome 
(UPD(14)pat) 
UPD(14)pat 
del(14q32)mat 
MEG3 hyperm. 
65.4% 
19.2% 
15.4% 
- 
- 
NR 
IUGR, polyhydramnion, abdominal and 
thoracal wall defects, bell-shaped thorax, 
coat-hanger ribs 
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(n=34)[42] 
Angelman syndrome 
(AS) 
15q11q13 UPD(15)pat 
del(15q11q13)mat  
aberrant methyl. 
UBE3A mutations 
1-2% 
75% 
~3% 
5-10%** 
- 
- 
- 
- 
mental retardation, microcephaly, no speech, 
unmotivated  laughing, ataxia, seizures 
Prader-Willi 
syndrome (PWS) 
UPD(15)mat 
del(15q 11q13)pat 
aberrant methyl. 
25-30% 
70-75% 
~1%** 
 
- 
- 
1 case 
PNGR, mental retardation, neonatal 
hypotonia, hypogenitalism, 
hypopigmentation, obesity/ hyperphagia 
Precocious puberty 15q MKRN3 mutations Unknown 5 families Precocious puberty (girls: 5.75 years, boys: 
8.10 years) 
Pseudohyperparathyre
oidism  
20q13 UPD(20)pat; 
aberrant methyl. 
Unknown - 
12.5% 
Resistance to PTH and other hormones; 
Albright hereditary osteodystrophy; 
Subcutaneous ossifications 
Feeding behaviour anomalies; Abnormal 
growth  
UPD(20)mat 20 UPD(20)mat Unknown 9 cases IUGR, PNGR, failure to thrive 
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Table 2 
 
Method Description Loci per 
test 
Detection of Advantages Disadvantages 
U
P
D
 
E
p
i
m
u
t
a
t
i
o
n
 
C
N
V
 
S
N
V
 
Single locus tests 
MS Southern 
Blot 
Classical Southern-Blot analysis using 
methylation-sensitive restriction 
endonucleases to differentiate between 
methylated and unmethylated alleles 
1 Y Y Y N Semi-quantitative 
Large amounts of DNA, 
time-consuming, no 
discrimination between the 
different types of 
(epi)mutations, low 
sensitivity 
Bisulfite 
sequencing 
Primary amplification of bisulphite-treated 
DNA by primers not discriminatory for 
methylation status of amplicon, followed by 
cloning of amplicons, and sequencing of 
bisulfite-altered differentially methylated 
cytosines within individual clones 
1* Y Y N N Semi-quantitative (amplification bias!) 
Time consuming, costly, 
cloning needed, no 
discrimination between the 
different types of 
(epi)mutations 
MS PCR 
Single-tube assay amplifying bisulfite-treated 
DNA with one common labelled primer and 
two primers specific to methylated or 
unmethylated sequence, giving differently-
sized products distinguished by genotyping 
1 Y Y Y N Fast, cheap, semi-quantitative 
no discrimination between 
the different types of 
(epi)mutations 
QAMA real-
time PCR-based 
qPCR assay to differentiate between 
methylated and unmethylated alleles by the 1 Y Y Y N Fast, quantitative  
no discrimination between 
the different types of 
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methylation 
assay 
use of differentially labeled probes (epi)mutations  
Microsatellite 
analysis (STR) 
Amplification of microsatellite repeat 
sequences followed by resolution of 
amplicon sizes to determine inheritance 
pattern of alleles 
1 Y N Y N Fast, cheap, quantification possible 
DNA of at least one parent 
required; no discrimination 
between the different types 
of (epi)mutations; 
microsatellites only in 
genomic vicinity of DMRs 
MS HRM 
Primary amplification of bisulphite-treated 
DNA by primers not discriminatory for 
methylation status of amplicon, followed by 
high-resolution DNA melting analysis to 
distinguish melting characteristics of 
differentially methylated alleles 
1 Y Y Y N Fast, cheap, semi-quantitative 
no discrimination between 
the types of (epi)mutations 
Multi-Locus tests 
MS 
pyrosequencing 
Primary amplification of bisulphite-treated 
DNA by primers not discriminatory for 
methylation status of amplicon, followed by 
sequence detection of bisulfite-altered 
differentially methylated cytosines within 
amplicon 
several Y Y Y N Fast, quantitative no discrimination between the types of (epi)mutations 
MS-MLPA 
(Methylation-
specific 
multiplex 
ligation-
dependent 
probe 
amplification) 
locus-specific MLPA probe-pairs hybridize 
to DNA. A successful binding of both probes 
allows their ligation and subsequent 
amplification. The parallel use of a 
methylation-sensitive restriction enzyme 
allows DNA quantification and determination 
of the methylation status  
Up to ~46 Y Y Y N 
Ready to use kits. 
Free and easy to use 
analysis software. 
Direct discrimination of 
CNVs and Epimutations. 
 
 
Mostly bound to already 
available kits  
Relatively high DNA Quality 
needed. 
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MS-SNuPE 
(Methylation-
specific single 
nucleotide 
primer 
extension) 
based on the ABI PRISM SNaPshot 
Multiplex kit using bisulfite converted DNA 
and specific SNuPE-Primers. The primers are 
designed to hybridize directly in front of a 
known CpG. The use of ddNTPs in the 
sequencing reaction allows a single-base 
difference depending on the methylation 
status of the amplified allele.  
Up to 10 Y Y Y N 
Flexible and adjustable 
use of SNuPE Primers.  
Cheap 
 
Primers not commercially 
available. 
Mostly self-made analysis 
software. 
Only indirect discrimination 
of CNVs and Epimutations. 
Molecular 
Karyotyping 
(arrayCGH, 
SNP array) 
Cohybridization of genomic DNA to 
complementary DNA fragments or 
hybridization to oligonucleotides spotted on 
an array surface. Resolution depends on the 
number of spotted DNA fragments and their 
distribution. Two main techniques are 
available: 
Array CGH -Comparative genomic 
hybridization: comparison of a test sample 
and reference sample allows the 
identification of relative copy number 
changes. 
SNP Array: test samples are compared in-
silico to a reference genome. Spotted DNA-
Fragments include SNPs  
Whole 
genome: 
depends 
on 
resolution 
Y 
(SNP) 
N 
(CGH) 
N Y N 
Fast technique to obtain 
whole genome CNV 
information. 
 
Relatively cheap 
 
Detection of low-level 
mosaicism  
 
Only unbalanced alterations 
are detected. 
Does not detect 
Epimutations, and in case of 
arrayCGH, not UPDs 
MS-Array, e.g. 
Infinium 450K 
With a comparable approach to the 
conventional molecular Array technology 
methylation specific Arrays use bisulfite 
converted DNA for analysis which can 
hybridize to genomewide CpG sites spotted 
to the Arrays surface.  
~ 475k 
CpGs, of 
which 
100s in 
DMRs of 
classically 
Y Y Y N 
Genomewide CpG 
coverage 
 
Expensive 
Relatively low resolution 
(only covers CpGs) 
Not all differentially 
methylated regions are 
represented on the array, 
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imprinted 
genes 
though coverage of most is 
excellent 
NGS / RRBS / 
WGBS 
 
Next generation sequencing (NGS)/RRBS 
(reduced representation bisulphate 
sequencing )/WGBS (whole genome 
bisulphate sequencing) describes massive 
parallel non-Sanger-based high-throughput 
DNA sequencing technologies of either 
genomic or bisulfite treated DNA.  
Assay 
dependent
: up to 
whole 
genome 
Y Y Y Y 
Whole genome / 
epigenome can be 
analysed at once 
 
Price per base relatively 
low 
 
 
 
Detection of low-level 
mosaicism 
Repetitive regions/ CG rich 
regions have an impact on 
coverage and therefore might 
hinder the analysis 
 
 
Large data challenges 
requiring advanced 
bioinformatics infrastructure 
and knowledge. 
 
Incomplete bisulphite 
modification has to be 
considered 
 
 
MeDIP 
Methylated DNA immunoprecipitation 
(MeDIP or mDIP) uses antibodies against 5-
methylcytosine (5mC) to enrich methylated 
DNA sequences in a genome wide or 
chromosome wide scale. The enriched 
methylated DNA can be used for downstream 
high throughput applications like NGS 
MeDIPseq or array based methods (MeDIP-
chip) 
 
Assay 
dependent
: up to 
whole 
genome 
 
 
Y Y (Y) N 
Genomewide CpG 
coverage on methylated 
regions 
 
Cross reactivity of 
antibodies, no single CpG 
resolution 
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Point 
mutation
Maternal 
Chromosome
Paternal 
Chromosome
2x
1x
1x
CH3
CH3
2x
1x
0x
CH3
Epimutation
CH3
CH3
2x
1x
0x
CH3
CH3
Maternal UPD
2x
2x
0x
CH3CH3
Paternal Deletion
2x
1x
0x
CH3
CH3
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
100%
50%
0%
2019000 2020000 2021000 2022000 2023000 2024000
Southampton 
(MS PCR)
Aachen
(SNuPE)
Barcelona
(Pyro)
Paris
(qPCR)
*** *
100%
50%
0%
2720500 2721000 2721500 272200
H19 DMR 
**** *
Barcelona
(Pyro)
Aachen
(SNuPE)
KvDMR1 DMR 
Southampton (MS PCR)
Paris
(qPCR)
M
e
t
h
y
l
a
t
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n
*
M
e
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h
y
l
a
t
i
o
n
*
Physical position on chromosome 11 (hg19)
Physical position on chromosome 11 (hg19)
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Diagnostic:
Single locus tests
Multilocus tests
Deep sequencing
Array analysis
Clinical 
characterisation:
Patient recording
HPO
Common 
questionnaires
Standardised 
Documentation:
Public databases 
(e.g. LOVD)
Common 
nomenclature
Therapy:
Evidence based,
new strategies (e.g. iPS cells, 
CRISP/CAS9, models),
Conventional therapies
Research:
MS arrays
MeDIP
Whole exome NGS
Whole epigenome NGS
Whole genome NGS
Genetic 
counselling
Guidelines
Consensus papers
Diagnostics
Research
Management
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Highlights 
 
- Imprinting disorders (IDs) are a group of congenital diseases affecting growth, development 
and metabolism.  
- IDs are caused by changes in the allele-specific regulation (“epigenetic mutation”) or in the 
genomic sequence (“genetic mutation”) of imprinted genes.  
- The application of single locus tests restrict diagnostic yield. 
- A standardization in testing methodology, in the DNA sequences tested, and in clinical 
inclusion criteria prompting testing is urgently needed.  
- The application of efficient and hight-throughput molecular techniques lead to an impressive 
increase of knowledge on IDs and their basic pathomechanisms.  
- The diagnostic strategies will be based on standardized protocols, and provide the backbone 
for directed counselling, more personalized management, and new therapeutic approaches.  
 
 
 
